What is Grace Therapeutics, Inc. (GRCE) stock price today?

Grace Therapeutics, Inc. (GRCE) currently trades at $2.10 per share. The stock has a market capitalization of $33.42M and a P/E ratio of —x.

Is GRCE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Grace Therapeutics, Inc. has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 2.71.

Is Grace Therapeutics, Inc. financially healthy?

Grace Therapeutics, Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 2.71 places it in the grey zone.

GRCE

Grace Therapeutics, Inc.

NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY

$2.10

+0.00% today

Updated 2026-04-29

Market cap

$33.42M

P/E ratio

—

P/S ratio

197.75x

EPS (TTM)

$-0.31

Dividend yield

—

52W range

$2 – $5

Volume

0.8M

Market cap

$33.42M

P/E ratio

—

P/S ratio

197.75x

EPS (TTM)

$-0.31

Dividend yield

—

52W range

$2 – $5

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.8

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

2.7

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$6.02

+186.67%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-2.22M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-9.82M	$-42.43M	$-12.85M	$-9.57M	$-3.18M
EPS	—	—	—	—	$-0.31
Free cash flow	$-17.23M	$-15.93M	$-12.36M	$-14.90M	$-2.22M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GRCE	$33.42M	27	4.3	3.0	5.0	6.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Grace Therapeutics, Inc. trades at $2.10. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.71, it sits in the grey zone.

Frequently asked questions

What is Grace Therapeutics, Inc.'s stock price?

Grace Therapeutics, Inc. (GRCE) trades at $2.10.

Is Grace Therapeutics, Inc. overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Grace Therapeutics, Inc. (GRCE)?

The analyst target price is $6.02, representing +186.7% upside from the current price of $2.10.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

2.71 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.gracetx.com

Quick metrics

P/S ratio197.75x

ROE-10.20%

Beta0.69

50D MA$4.07

200D MA$3.46

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GRCE vs LLY →GRCE vs JNJ →GRCE vs ABBV →Stock screener →